We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Dechra Pharmaceuticals Plc | DPH | London | Ordinary Share |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 3,866.00 | 01:00:00 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 3,866.00 |
| Industry Sector |
|---|
| PHARMACEUTICALS & BIOTECHNOLOGY |
| Top Posts |
|---|
Posted at 10/5/2023 09:31 by phillis Am not up to date with the rulesDPH could agree to an extension I think |
Posted at 05/9/2022 15:04 by km18 Dechra Pharmaceuticals Plc posted Prelims for the FY ended 30th June 2022. Revenues grew 13.8% to £681.8 million, reported operating profit rose 16.2% to £95.5m, underlying diluted EPS increased 14.0% to 120.84 pence and the FY dividend increased by 10.8% to 44.89 pence, all at constant exchange rate. The business has been growing solidly for many years now, but valuation remains unhelpful with forward PE ratio at 27.9x and PS ratio at 6.21x. Share price has been in a correction for most of 2022 and this correction has extended another 10%+ following today’s release. DPH is a high quality and solid growth business, but it is expensive and a share to monitor for now......from WealthOracle |
Posted at 02/8/2022 09:08 by spyder Anyone know what has rattled DPH this morning? |
Posted at 09/5/2022 14:29 by montyhedge rogueYour right, very high p.e stocks with tiny dividends, not the place to be, low p.e high dividend payers, rotation still going on. |
Posted at 21/2/2022 13:18 by km18 Dechra Pharmaceuticals issued its HY Financial Report this morning. Reported Group revenue for the period increased by 15.9% to £332.4m at Constant Exchange Rate (CER). Underlying operating profit growth was 22.0% with underlying operating margin improving by 140 bps to 28.2%. Underlying diluted EPS growth was 24.0% to 64.01p and the interim dividend increased by 8.0% to 12 pence. So more robust growth and more profitable growth.The business has been growing briskly and profitably for many years now and looks set to continue this pattern in FY22 as well. Unsurprisingly investors have already bought into the story, valuation is rich with forward PE ratio around 31 and bottom quartile for the Pharma sector. The share price is also currently in a 30%+ correction and still falling after a powerful post-Covid rally. DPH is a very good company delivering persistent and robust growth, but there is no rush to buy. Monitor for the time being.... ...from WealthOracleAM |
Posted at 28/9/2021 08:35 by deanroberthunt The company on Monday said underlying operating profit increased by 29.2% to £162.2m on the back of revenue growth of 21.0% to £608.0m. The full-year dividend rose 18.1% to 40.50p a share.On a pre-tax basis profit for the year through to June 30 almost doubled to £74m, up from £40.9m. “We have benefited from above average market growth in the majority of our key companion animal product markets. The reasons for this market growth are not yet fully defined,” said chief executive Ian Page. |
Posted at 30/8/2021 09:53 by whatja DPH is being touted for a potential promotion to the FTSE100.This is because BHP is delisting and JET is reclassified as non-UK because most trading is now is US following a takeover. |
Posted at 07/9/2020 07:56 by steeplejack The interim dividend was up 8.3% so the final dividend has been increased by a similar amount.The earnings figures are modestly ie about 2% better than consensus,broadly in line. |
Posted at 07/9/2020 07:50 by lasata Was the increased dividend expected? |
Posted at 07/9/2020 07:34 by lasata Ok results...nothing special. Good to see dividend is up |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
